CareDx, Inc 8-K

Summary

CareDx completed the sale of its Lab Products business to Eurobio on 6/30/2026 and acquired specialty oncology diagnostics company Naveris on 7/1/2026. The sale sharpens CareDx’s focus on U.S. precision medicine testing services and patient and digital solutions, while Naveris adds repeat molecular testing in specialty oncology to its transplant and cell therapy businesses.

Key Figures

• Eurobio acquired CareDx AB and assets related to the Lab Products business: PCR kits for deceased-donor human leukocyte antigen typing, sequencing-based kits for transplant-recipient typing, and monitoring assays for transplant recipients outside North America. The 8-K reports $171.7M in aggregate cash consideration; the closing announcement reports $171.2M received at closing. Both figures are subject to customary adjustments.
• CareDx paid $161.8M in cash for Naveris, with up to an additional $100M payable to Naveris equityholders if revenue-based milestones are met for fiscal years ending 12/31/2026 and 12/31/2027.
• Naveris’s lead product, NavDx, is a blood test that detects and monitors viral-mediated cancers, including HPV-associated head and neck and anal cancers, and is the only Medicare-covered test for molecular residual disease in those cancers. More than 130,000 tests have been commercially reported; its 2025 revenue was approximately $35M, more than double Y/Y. Its Medicare reimbursement rate is $1,800, and CareDx estimates its addressable U.S. market across transplant, specialty oncology and cell therapy at more than $12B.
• Naveris will be included in CareDx’s consolidated results beginning in Q3 2026.

Investor Takeaways

• Track NavDx test volumes and Naveris revenue as CareDx begins consolidation in Q3 2026; progress against the 2026 and 2027 revenue milestones determines whether equityholders receive additional consideration.
• CareDx expects to discuss the sale’s financial impact, including pro forma results, on its Q2 2026 earnings call.